Get the latest tech news
Struggling 23andMe Is Exploring Splitting the DNA Company In Two
In a recent interview with Bloomberg, 23andMe CEO Anne Wojcicki said the company was considering splitting its consumer and therapeutics businesses in an effort to boost its stock price and maintain its listing. From a report: Bloomberg noted that the stock has lost more than 90% of its value since...
In a recent interview with Bloomberg, 23andMe CEO Anne Wojcicki said the company was considering splitting its consumer and therapeutics businesses in an effort to boost its stock price and maintain its listing. From a report: Bloomberg noted that the stock has lost more than 90% of its value since the company went public in 2021 through a SPAC merger. 23andMe's stock has been trading below $1 since December, hurt by revelations that hackers were able to access the personal information of around 50% of its subscribers.
Or read this on Slashdot